BridgeBio Oncology Therapeutics (BBOT) investor relations material

Executive summary

• Advanced three lead clinical-stage oncology programs targeting RAS and PI3K pathways, with two receiving FDA Fast Track designation and ongoing Phase 1 trials for all candidates.

• Advanced monotherapy and combination cohorts for all clinical programs, with meaningful progress in patient enrollment and new dosing regimens initiated.

• Presented preclinical data showing strong efficacy of BBO-11818 and BBO-10203 in relevant tumor models.

• Reported net losses of $56.5 million for Q2 2026 and $98.6 million for the first half of 2026, reflecting increased R&D and G&A expenses post de-SPAC transaction.

• Maintained a strong liquidity position with $344.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $344.1 million as of June 30, 2026, down from $425.5 million at year-end 2025.

• Research and development expenses rose 79% year-over-year to $49.2 million for Q2 2026, driven by higher clinical trial and manufacturing costs.

• General and administrative expenses increased 313% year-over-year to $11.0 million for Q2 2026, reflecting headcount growth, public company costs, and one-time severance.

• Net loss widened to $56.5 million in Q2 2026 from $28.4 million in Q2 2025.

• Interest income more than doubled to $3.6 million in Q2 2026 due to higher cash balances from the de-SPAC and PIPE financing.

Outlook and guidance

• Existing cash and marketable securities are expected to fund operations into 2028, but additional capital will be needed to complete development and commercialization of product candidates.

• Multiple near-term clinical milestones and updated clinical data for lead programs expected in the second half of 2026.

• Anticipates continued increases in operating expenses as clinical programs advance and public company infrastructure expands.